Skip to main content
SpringerLink
Log in

Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

MECOM gene, also known as EVI, encodes a transcriptional regulator involved in hematopoiesis, apoptosis, development and proliferation. In blood system, MECOM is considered an oncogene, but in solid tumors it has both oncogenic and tumor suppressor activities. Low frequent somatic mutations of MECOM have been detected in many cancers including colorectal cancers (CRC), but the mutation status with respect to the microsatellite instability (MSI) has not been studied. There is an A7 mononucleotide repeat in MECOM coding sequences that could be a mutation target in the cancers with MSI. We analyzed the A7 of MECOM in 79 CRCs with high MSI (MSI-H) and 65 microsatellite stable/low MSI (MSS/MSI-L) CRCs by single-strand conformation polymorphism analysis and DNA sequencing. Overall, we found MECOM frameshift mutations in 6 (7.6 %) CRCs with MSI-H, but not in MSS/MSI-L cancers (0/65) (p < 0.025). We also analyzed intratumoral heterogeneity (ITH) of the MECOM frameshift mutation in 16 CRCs and found that four CRCs (25.0 %) harbored regional ITH of the frameshift mutations. Our data indicate that MECOM gene harbors both somatic frameshift mutations and mutational ITH, which together may be features of CRC with MSI-H.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Weiser R (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396:346–357

    Article  Google Scholar 

  2. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS, Ihle JN, Mucenski ML (1997) The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 65:55–70

    Article  CAS  PubMed  Google Scholar 

  3. Kilbey A, Stephens V, Bartholomew C (1999) Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in evi-1 transformed fibroblasts. Cell Growth Differ 10:601–610

    CAS  PubMed  Google Scholar 

  4. Alliston T, Ko TC, Cao Y, Liang YY, Feng XH, Chang C, Derynck R (2005) Repression of bone morphogenetic protein and activin-inducible transcription by evi-1. J Biol Chem 280:24227–24237

    Article  CAS  PubMed  Google Scholar 

  5. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H (1998) The oncoprotein evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 394:92–96

    Article  CAS  PubMed  Google Scholar 

  6. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y, Hirai H (2000) The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 19:2958–2968

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA (2006) Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene 25:3565–3675

    Article  CAS  PubMed  Google Scholar 

  8. Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, Ni H, Saunthararajah Y, Nucifora G (2004) EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 114:713–719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Morishita K, Parganas E, William CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN (1992) Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci U S A 89:3937–3941

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Nucifora G, Rowley JD (1995) AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86:1–14

    CAS  PubMed  Google Scholar 

  11. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang JM, Guan XY, Trent J, Alberts DS, Taetle R (1996) Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer 74:1518–1525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nanjundan M, Nakayama Y, KW C, Lahad J, Liu J, K L, WL K, Smith-McCune K, Fishman D, JW G, GB M (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67:3074–3084

    Article  CAS  PubMed  Google Scholar 

  13. Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, Chin G, Luke JJ, Ott PA, Hodi FS, MC JM, Lin JY, Werchniak AE, Haynes HA, Bailey N, Liu R, Murphy GF, Lian CG (2015) Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics 7:59

    Article  PubMed  PubMed Central  Google Scholar 

  14. Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680

    Article  CAS  PubMed  Google Scholar 

  15. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334

    Article  CAS  PubMed  Google Scholar 

  16. McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15–26

    Article  CAS  PubMed  Google Scholar 

  17. Kim TM, Jung SH, Baek IP, Lee SH, Choi YJ, Lee JY, Chung YJ, Lee SH (2014) Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer. J Pathol 233:425–435

    Article  CAS  PubMed  Google Scholar 

  18. Murphy K, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR (2006) Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 8:305–311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Oh HR, An CH, Yoo NJ, Lee SH (2015) Frameshift mutations of MUC15 gene in gastric and its regional heterogeneity in gastric and colorectal cancers. Pathol Oncol Res 21:713–718

    Article  CAS  PubMed  Google Scholar 

  20. Choi MR, An CH, Yoo NJ, Lee SH (2015) Laminin gene LAMB4 is somatically mutated and expressionally altered in gastric and colorectal cancers. APMIS 123:65–71

    Article  CAS  PubMed  Google Scholar 

  21. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495–501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A, Santos A, Lopez-Bigas N (2013) IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods 10:1081–1082

    Article  CAS  PubMed  Google Scholar 

  24. Calin GA, Gafà R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G (2000) Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: a study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. Int J Cancer 89:230–235

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from National Research Foundation of Korea (2012R1A5A204793).

Author information

Authors and Affiliations

  1. Department of Pathology, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Socho-gu, Seoul, 137-701, Korea

    Eun Ji Choi, Min Sung Kim, Nam Jin Yoo & Sug Hyung Lee

  2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Sang Yong Song

Authors
  1. Eun Ji Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Sung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang Yong Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nam Jin Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sug Hyung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sug Hyung Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choi, E.J., Kim, M.S., Song, S.Y. et al. Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability. Pathol. Oncol. Res. 23, 145–149 (2017). https://doi.org/10.1007/s12253-016-0112-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-016-0112-3

Keywords

Search

Navigation